Return to top of page

User Fee Agreements

User Fee programs help the Food and Drug Administration (FDA) to ensure timely review and support the development of innovative therapeutics. The FDA Reauthorization Act of 2017 reauthorized the pharmaceutical, medical device, generic drug, and biosimilar user fee agreements until 2022. The Alliance played an important role in the input process for the legislation, including enhancing regulatory science and expediting drug development, hiring of FDA staff, and patient-focused drug development (PFDD).

The Alliance continues to serve as a valued voice for patients in the user fee process and is currently engaged with the FDA in stakeholder discussions for the next round of user fee agreements to begin in 2022.

The Healthy Aging Blog on User Fee Agreements

News & Updates on User Fee Agreements

Candid Seal of Platinum Transparency 2022

The Alliance for Aging Research is a proud recipient of Candid’s Platinum Seal of Transparency.

Charity Navigator logo

The Alliance for Aging Research is proud to be rated a 4-star charity by Charity Navigator.